I'm optimistic that the S&P/ASX 200 Index (ASX: XJO) will continue to break records in 2025.
But unfortunately, it is impossible to know what will happen with any certainty.
And while a stock market crash would be disappointing next year, I think it is important not to fear such an event. Instead, investors should see a crash as an opportunity to load up on high-quality ASX 200 shares at good prices.
With that in mind, let's take a look at a couple of ASX 200 shares that could be strong buys if the market pulled back. They are as follows:
The first ASX 200 share that could be a buy if the stock market crashes is Life360.
It is a growing family connection and safety company that aims to keep people close to the ones they love. Its category-leading mobile app, the Life360 app, provides location sharing, safe driver reports, and crash detection with emergency dispatch to a massive 76.9 million monthly active users (MAU) across more than 170 countries.
Bell Potter is bullish on the company and believes it is well-placed for long-term growth. Its analysts recently said:
Life360 operates a market-leading app that provides communication, driving safety, and location-sharing features. With over 70 million monthly active users and 2 million paying circles, the company has significant growth potential as it continues to rapidly monetise its customer base.
Bell Potter currently has a buy rating and $26.75 price target on its shares.
Pro Medicus could be an ASX 200 share to buy in the event of a stock market crash. It is a leading health imaging technology provider, delivering services and solutions to hospitals, imaging centres, and healthcare groups worldwide.
Goldman Sachs is a big fan of the company and believes it has a significant long-term opportunity. It recently said:
We remain positive on the PME equity story as one of Australia's best global growth companies. […] PME is not cheap, trading on 114x FY26E EV/EBITDA, but we highlight its revenue/margin outlook, unique cloud offering, and significant long-term opportunity. Additionally, with a focus on the US regulatory outlook, we believe MedTech is increasingly being evaluated as a safe haven within healthcare as it is generally more insulated from impending policy volatility.
Goldman Sachs currently has a buy rating and $278.00 price target on its shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.